ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: L18 • ACR Convergence 2024

    CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis

    Wei Guo1, Zhaohua Li2, Dan Xu2 and Rong Mu2, 1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, 2Peking University Third Hospital, Beijing, China

    Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L06 • ACR Convergence 2024

    Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies

    Raphael Kirou1, Iago Pinal-Fernandez1 and Andrew Mammen2, 1NIAMS/National Institutes of Health, Bethesda, MD, 2NIH, Bethesda, MD

    Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
  • Abstract Number: 0327 • ACR Convergence 2024

    Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

    Samuel Govea-Peláez1, Beatriz Alcalá-Carmona2, Jennifer Balderas Miranda3, Yatzil Reyna-Juárez2, María José Ostos-prado2, Nancy R Mejía-Domínguez2, Guillermo Juarez-Vega4, Jiram Torres Ruiz5 and Diana Gomez-martin6, 1INCMNSZ, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Mexico, Federal District, Mexico, 6INCMNSZ, Mexico City, Federal District, Mexico

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
  • Abstract Number: 0955 • ACR Convergence 2024

    Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis

    Goncalo Boleto1, Anne Cauvet2, James Rose3, Lih-Yun Hsu3, Richard A. Miller3 and Yannick Allanore4, 1Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, 2Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, 3Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, 4Université Paris Cité, Paris, France

    Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
  • Abstract Number: 1799 • ACR Convergence 2024

    In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus

    Jia Xin Chow1, Rochelle Sherlock2, Taylah Bennett2, Eric Morand3 and Sarah Jones2, 1Monash University, Melbourne, Victoria, Australia, 2Monash University, Melbourne, Australia, 3School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
  • Abstract Number: 0342 • ACR Convergence 2024

    Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis

    Sung Ik Cho1, Miriam Kim2, Ju yeon Kim3, Jin Kyun Park4, Eun Young Lee5, eun Bong Lee6 and Jun Won park3, 1Seoul National University Hospital, Jongno-gu, Seoul-t'ukpyolsi, Republic of Korea, 2Seoul National University, Seoul, Republic of Korea, 3Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 4Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 53Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 6Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: To investigate whether serum levels of cytokine and chemokine can predict a treatment response in patients with idiopathic inflammatory myositis (IIM)Methods: This study included…
  • Abstract Number: 1132 • ACR Convergence 2024

    Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy

    Dylan Richards1, Marion Vetter1, Matthew Germinaro1, Bram Verstockt2, Raja Atreya3, Julián Panés4, Bruce E. Sands5, Brian G. Feagan6, Bradford McRae7, Daniel Cua1, Patrick Branigan1 and Tom C. Freeman1, 1Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, 2Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium, 3Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, 4Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, Barcelona, Spain, 5Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY, 6Alimentiv Inc, London, ON, Canada, London, ON, Canada, 7Janssen Research & Development, Cambridge, MA, USA, Cambridge, MA

    Background/Purpose: Combination induction therapy with guselkumab (GUS), an interleukin (IL)-23p19 subunit antagonist, and golimumab (GOL), a tumor necrosis factor (TNFα) antagonist, induced higher rates of…
  • Abstract Number: 1801 • ACR Convergence 2024

    Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus

    Tania Rowley1, Adnan R. Khan1, Laura McLaughlin1, Hannah Cherry1, Farnaz Fallah-Arani1, Yiannis Ioannou1, Debasish Pyne2 and Anthony Shock1, 1UCB Pharma, Slough, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
  • Abstract Number: 0396 • ACR Convergence 2024

    Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood

    Maryrose Hahn1, Madison Mangin2, Kellen Winden3, Pui Lee4, Mindy Lo2, Bharti Nihalani-Gangwani2, Yasmin Massoudi5, Tate Valerio5, Amanda Colombo5, Jessica Scott6, Stephen Anesi6, C. Stephen Foster6, Peter Nigrovic7, sheila Angeles-Han8, Peter Chang6 and Margaret Chang2, 1Boston Children's Hospital, Georgetown, MA, 2Boston Children's Hospital, Boston, MA, 3Boston Children's Hospital, Boston, MA, 4Boston Children's Hospital, Newton, MA, 5Massachusetts Eye Research and Surgery Institution, Waltham, MA, 6Massachusetts Eye Research and Surgery Institution, Waltham, 7Boston Children's Hospital, Brookline, MA, 8Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
  • Abstract Number: 1197 • ACR Convergence 2024

    Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients

    François Rannou1, Christelle Nguyen1, Camille Daste1, Quentin Kirren1, marie-martine Lefevre-Colau1, Odile Launay2, Lucille Desallais3, Edita Dolimier3, René Azoulai3, Jean-Pierre Salles3 and Jean-François Zagury4, 1AP-HP. Centre-Université Paris Cité, Hôpital Cochin, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Paris, Ile-de-France, France, 2Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France, 3Peptinov, Paris, Ile-de-France, France, 4Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, EA 7528, Chaire de Bioinformatique, Conservatoire National des Arts et Métiers, Paris, Ile-de-France, France

    Background/Purpose: Interleukin-6 (IL-6) is a major inflammatory cytokine involved in pain and potentially in osteoarthritis (OA) disease progression. PPV-06 is an IL-6-derived peptide coupled with…
  • Abstract Number: 1782.5 • ACR Convergence 2024

    Monocytes from HLA B27 Positive Enthesitis Related Arthritis Patients Are More Activated Than HLA B27 Negative Patients

    Shivika Guleria1, Anu Balakrishnan1, Able Lawrence1 and Amita Aggarwal2, 1SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA similar to Spondylarthritis…
  • Abstract Number: 0408 • ACR Convergence 2024

    Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study

    Michael Matt1, Mariana Correia Marques2, Sabrina Fuehner3, Lexi Auld1, George Tomlinson4, Michael Ombrello5, Yukiko Kimura6, Christoph Kessel7 and grant schulert1, and the CARRA FROST Investigators, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2National Institutes of Health, Bethesda, MD, 3Universitaetsklinikum Muenster, Muenster, Germany, 4University of Toronto, Toronto, ON, Canada, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 6Hackensack Meridian School of Medicine, New York, NY, 7University Hospital Muenster, Muenster, Germany

    Background/Purpose: IL-1 inhibitors are both widely used and highly effective as first-line therapy for children with systemic juvenile idiopathic arthritis (sJIA); however, the mechanisms underlying…
  • Abstract Number: 1349 • ACR Convergence 2024

    Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis

    Jasmine Sim1, Nandhini Ramamoorthi2, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Anna Guttman4, Andrew Melville5, Nisha Rathore2, Stefan Siebert5, Iain McInnes6, Carl Goodyear5, Catharien Hilkens1, Andrew Filer7, Karim Raza7, Christopher Buckley8, Arthur Pratt1, James Wason9, Amy Anderson1, Michael Townsend2, Kenneth Baker1 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Genentech, South San Francisco, CA, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4Genentech, South San Franscisco, CA, 5School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 6University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 7Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 8Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 9Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
  • Abstract Number: 1845 • ACR Convergence 2024

    Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis

    Amy Anderson1, Luke Jones2, Fiona Rayner3, Jessica Swift1, Daniel Maunder1, Henrique de Paula Lemos1, David Swan4, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Gary Reynolds1, Jasmine Sim1, Andrew Melville5, Stefan Siebert5, Iain McInnes6, Carl Goodyear5, Catharien Hilkens1, Karim Raza7, Christopher Buckley8, Kenneth Baker1, Arthur Pratt3, Andrew Filer7 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 5School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 6University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 7Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 8Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology